Comparison · NCT03703310-sae
Patidegib Topical Gel, 2%, vs Patidegib Topical Gel, Vehicle: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Patidegib Topical Gel, 2%, vs Patidegib Topical Gel, Vehicle: serious adverse events. Trial comparisons, record NCT03703310-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03703310-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0575 | 0.0248 | 0.128 | wilson | |
| Risk in group 2 | 0.0805 | 0.0395 | 0.157 | wilson | |
| Risk difference, group 1 minus group 2 | -0.023 | -0.106 | 0.0582 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.714 | 0.236 | 2.16 | log | |
| Odds ratio, group 1 over group 2 | 0.697 | 0.212 | 2.29 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Patidegib Topical Gel, 2%, than on Patidegib Topical Gel, Vehicle | 43.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: vehicle.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Patidegib Topical Gel, 2%, | Participants will be randomized to receive Patidegib Topical Gel, 2%. The Patidegib Topical Gel, 2% will be dispensed to participants at each study visit and applied topically twice daily to the face.~Patidegib Topical Gel, 2%: Patidegib Topical Gel, 2% | 5 | 87 | EG000 |
| Group 2 | Patidegib Topical Gel, Vehicle | Participants will be randomized to receive Vehicle. The Patidegib Topical Gel, Vehicle will be dispensed to participants at each study visit and applied topically twice daily to the face.~Patidegib Topical Gel, Vehicle: Patidegib Topical Gel, Vehicle | 7 | 87 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 1 year
Source ClinicalTrials.gov
Trial
- Title
- Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
- NCT number
- NCT03703310
- Phases
- PHASE3
- Conditions
- Basal Cell Nevus Syndrome
- Interventions
- Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle
- Lead sponsor
- Sol-Gel Technologies, Ltd.
- Results first posted
- 2024-07-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03703310?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03703310-sae